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Abstract
Erythrocyte invasion by Plasmodium merozoites is a complex, multistep process that is mediated by a number of parasite
ligand-erythrocyte receptor interactions. One such family of parasite ligands includes the P. falciparum reticulocyte binding
homologue (PfRH) proteins that are homologous with the P. vivax reticulocyte binding proteins and have been shown to
play a role in erythrocyte invasion. There are five functional PfRH proteins of which only PfRH2a/2b have not yet been
demonstrated to bind erythrocytes. In this study, we demonstrated that native PfRH2a/2b is processed near the N-terminus
yielding fragments of 220 kDa and 80 kDa that exhibit differential erythrocyte binding specificities. The erythrocyte binding
specificity of the 220 kDa processed fragment of native PfRH2a/2b was sialic acid-independent, trypsin resistant and
chymotrypsin sensitive. This specific binding phenotype is consistent with previous studies that disrupted the PfRH2a/2b
genes and demonstrated that PfRH2b is involved in a sialic acid independent, trypsin resistant, chymotrypsin sensitive
invasion pathway. Interestingly, we found that the smaller 80 kDa PfRH2a/2b fragment is processed from the larger 220 kDa
fragment and binds erythrocytes in a sialic acid dependent, trypsin resistant and chymotrypsin sensitive manner. Thus, the
two processed fragments of PfRH2a/2b differed with respect to their dependence on sialic acids for erythrocyte binding.
Further, we mapped the erythrocyte binding domain of PfRH2a/2b to a conserved 40 kDa N-terminal region (rPfRH240)i n
the ectodomain that is common to both PfRH2a and PfRH2b. We demonstrated that recombinant rPfRH240 bound human
erythrocytes with the same specificity as the native 220 kDa processed protein. Moreover, antibodies generated against
rPfRH240 blocked erythrocyte invasion by P. falciparum through a sialic acid independent pathway. PfRH2a/2b thus plays a
key role in erythrocyte invasion and its conserved receptor-binding domain deserves attention as a promising candidate for
inclusion in a blood-stage malaria vaccine.
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Introduction
Malaria is one of the major killer diseases of the world, which
causes an annual mortality of around one million deaths primarily
in infants and children less than 5 years [1]. The most severe and
fatal form of malaria, cerebral malaria is caused by the
apicomplexan parasite, P. falciparum. P. vivax is the other major
Plasmodium species that causes human malaria. P.vivax primarily
invades Duffy positive human erythrocytes, which is mediated by
the interaction of the P. vivax Duffy binding protein (PvDBP) with
the Duffy antigen (DARC) [2–4]. Unlike P.vivax, P. falciparum has
developed a high level of redundancy in receptor usage, which
enables erythrocyte invasion through multiple pathways [5–7].
Among the many parasite molecules that mediate erythrocyte
invasion by P. falciparum, there are two major protein families,
namely the Duffy binding-like family (DBL) and the Reticulocyte
binding homologues (RH) that have been shown to bind
erythrocytes [5–7]. The DBL family consists of five P. falciparum
homologues of PvDBP, namely, EBA-175, EBA-140 (BAEBL),
EBA-181 (JESEBL), EBL-1 and EBA-165 (PEBL) [5–7]. The
PfRH family consists of six P. falciparum homologues of the P. vivax
reticulocyte binding proteins (PvRBP), namely, PfRH1, PfRH2a,
PfRH2b, PfRH3, PfRH4 and PfRH5 [5–7]. The DBL proteins
are characterized by the presence of a conserved cysteine-rich
region that mediates erythrocyte binding [4,8]. While the DBLs
have been studied extensively, the PfRH proteins have been
discovered relatively recently and their functional characteristics
have yet to be completely defined.
PfRH2a and PfRH2b [9,10] were the first members of the
PfRH family to be identified followed by PfRH1 [11], PfRH4 [12]
and PfRH5 [13]. Like EBA-165 [14], PfRH3 is also a pseudogene
that is transcribed but not translated [15]. PfRH2a and PfRH2b
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appear to have arisen from a duplication event. Both genes are
located adjacently on chromosome 13 in a head to head
orientation [9,10,16,17]. These two genes are around 9 kb in
length and share an identical 8 kb region which codes for 2700
amino acids. The difference in the gene sequences arises towards
the 39end that accounts for around 500 amino acids towards the
C-terminal end. This unique region comprises of a part of the
ectodomain, the transmembrane region and the cytoplasmic tail
[9,10,16,17]. The identical ectodomain of PfRH2a and PfRH2b
comprising of 2700 amino acids is referred here as PfRH2a/b.
The interest in the PfRH family of proteins has been generated
by recent work that has shown that the expression of these proteins
correlates with the invasion phenotypes of different parasite lines
[16,18–21]. This was clearly demonstrated for PfRH4, whose
upregulation was found to mediate a switch from a sialic acid
dependent to sialic acid independent invasion phenotype in case of
the P. falciparum clone, Dd2 [19,20]. Similarly, it has been reported
that PfRH proteins are differentially expressed between parasite
lines with different invasion phenotypes [16,18,21]. The sialic acid
dependent lines such as Dd2, MCamp and FCR3 express higher
levels of PfRH1 and low levels of PfRH2a/2b [16,18,21]. On the
other hand, the sialic acid independent lines such as 3D7, HB3,
7G8 express higher levels of PfRH2a/2b and lower levels of
PfRH1 [16,18,21]. PfRH1, PfRH4 and PfRH5 have been shown
to exhibit erythrocyte binding activity [11,13,22–24]. The
erythrocyte binding domains of PfRH4 [23,24] and PfRH1[22]
have also been elucidated. Thus, among the five functional PfRH
proteins, all except PfRH2a/2b have been shown to bind
erythrocytes.
While previously the erythrocyte binding activity of PfRH2a/2b
could not be detected [10,16], the genetic disruption of PfRH2a
and PfRH2b demonstrated a role for PfRH2a/b in erythrocyte
invasion [16]. A comparison of the invasion phenotypes of the
PfRH2b knockout and wild type parasite lines showed that
PfRH2b mediates erythrocyte invasion through a sialic acid
independent, trypsin resistant, chymotrypsin sensitive pathway
[16]. In the same study, the disruption of the PfRH2a gene did not
produce any differences in invasion phenotypes between the
knockout and wild type parasites, implying that PfRH2a does not
play a primary role in this invasion pathway [16]. Further, a recent
study has reported that PfRH2a is also involved in sialic acid
independent invasion although PfRH2b has a more critical role in
this invasion pathway [25].
Based on this data, it appears that the PfRH2a and PfRH2b
proteins could also possess erythrocyte binding activity mediated
through regions in their ectodomains like other members of the
PfRH family. In this study, we report that full length native
PfRH2a/2b is processed in two steps that yield smaller fragments.
Further, we demonstrate for the first time that different processed
fragments of native PfRH2a/b bind erythrocytes with different
specificities. In addition, we have identified a 40 kDa N-terminal
region (rPfRH240), common to both PfRH2a and PfRH2b, which
binds erythrocytes with the same specificity as the native parasite
protein. This region of the PfRH2a/b native protein appears to
constitute its receptor binding domain. Our study is the first to
report the erythrocyte binding activity of PfRH2a/b and delineate
a region of the native protein that mediates its binding with
erythrocytes. We also demonstrate that the rPfRH240 domain is
immunogenic. The antibodies raised against this functional
domain recognize the native parasite protein and inhibit
erythrocyte invasion by P. falciparum in vitro. The ability of
antibodies raised against the functional domain of PfRH2a/b to
inhibit erythrocyte invasion suggests that it may be useful to
include rPfRH240 in a blood-stage vaccine against P. falciparum
malaria.
Materials and Methods
Ethics Statement
The animal studies described below were approved by the
ICGEB Institutional Animal Ethics Committee (IAEC Reference
No. MAL-51). ICGEB is licensed to conduct animal studies for
research purposes under the registration number 18/1999/
CPCSEA (dated 10/1/99).
Cloning of the PfRH2 constructs
A codon optimized gene of 1098 bp encoding 366 amino acids
(Ser 495 to Ile 860) of PfRH2a/b from P. falciparum 3D7 (rPfRH240)
with a C-terminal 6-histidine (6-His) tag was synthesized. The
regions of the native PfRH2a/b gene encoding the amino acid
sequence of rRH2-Pro1 (Met 76 to Asp 494) and rRH2-Pro4 (Asn
1599 to Ile 2059) were PCR amplified from 3D7 genomic DNA
using the following primers: RH2-Pro1F: GTGTgctagcAAGA-
GATCG CTTATAAATTTAG, RH2-Pro1R: TCTCctcgagATC-
CAG ATTTGCTTTTGGAT; RH2-Pro4F: GTGTgctagcAA-
CATTAAAAGAGAAGGTGATG, RH2-Pro4R: TCTCctcgagA-
ATATTATTTG AAATATCATTTTCTCT. The synthetic gene
encoding rPfRH240 and the PCR products encoding rRH2-Pro1
and rRH2-Pro4 were digested with Nhe Ia n dXho I (New England
Biolabs, Beverly, MA) and inserted downstream of the T7 promoter
in the E. coli expression vector, pET-24b (Novagen, San Diego, CA)
to obtain the plasmids pPfRH240-pET24b, pPfRH2-Pro1-pET24b,
pPfRH2-Pro4-pET24b respectively. Sequencing of the ligated
plasmids confirmed the correct sequence of the PfRh2a/b gene
fragments and that the insertions were in the correct reading frame.
Expression and purification of recombinant proteins and
generation of specific antisera
E. coli BL21(DE3) cells (Novagen, San Diego, CA) were
transformed with the expression plasmids and used to produce
the recombinant PfRH2a/b proteins. Transformed E. coli
BL21(DE3) were cultured in Luria broth at 37uC. Expression of
rPfRH240, rRH2-Pro1 and rRH2-Pro4 proteins was induced with
1 mM IPTG when OD600 of the culture was in the range of 0.6 to
0.8. Cells were grown for 4 hours after induction and were
harvested by centrifugation at 3000 g. Harvested cell pellets were
lysed by sonication and each of the three overexpressed proteins
were found in inclusion bodies. The inclusion bodies were
collected by centrifugation at 15000 g and solubilized in 8 M
Guanidine-HCL. The proteins were purified from solubilized
inclusion bodies by Ni-NTA (nitrilotriacetic acid) affinity chroma-
tography using standard methods and further purified as described
below.
Metal-affinity purified rPfRH240 protein was refolded by a 30-
fold rapid dilution in an L-Arginine based refolding buffer. The
refolding solution was incubated for 24 hours at 4uC with
continuous stirring, and then dialyzed against phosphate buffered
saline (PBS, pH 7.4). The dialyzed protein solution was applied on
a Q-sepharose anion exchange column (GE Healthcare, Piscat-
away, NJ) to purify rPfRH240.
Metal affinity purified (Ni-NTA) PfRH2a/b proteins – rRH2-
Pro1 and rRH2-Pro4 were run in an SDS-PAGE gel and the
proteins were eluted from the acrylamide for injection into mice.
The immunization schedule for these two proteins was the same as
followed for rPfRH240. Mice and rabbits were immunized
intramuscularly with 25 mg and 100 mg respectively of the
recombinant proteins emulsified with complete Freund’s adjuvant
PfRH2 Merozoite Protein Binds Human Erythrocytes
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with incomplete Freund’s adjuvant on days 28 and 56. The sera
were collected on day 70. Antibody levels were measured in the
sera by ELISA [26].
Erythrocyte Binding Assays (EBA)
Erythrocyte binding assays were performed as described earlier
[23]. Soluble parasite proteins were obtained from P. falciparum
3D7 culture supernatants of schizont-infected erythrocytes as
described previously [23]. Briefly, culture supernatants or
recombinant proteins were incubated with human erythrocytes
at 37uC following which the suspension was centrifuged through
dibutyl phthalate (Sigma, St. Louis, MO
The supernatant and oil were removed by aspiration. Bound
parasite proteins were eluted from the erythrocytes with 1.5 M
NaCl. The eluate fractions were analyzed for the presence of the
PfRH2a/b protein by immunoblotting using anti-rPfRH240 or
anti-rRH2-Pro1 antibodies.
Growth inhibition assays (GIA)
In the GIA assays, 6610
4 schizont-infected erythrocytes were
incubated with 2610
7 target erythrocytes in 100 ml of complete
RPMI medium containing IgG (5 mg/ml) purified from anti-
rPfRH240 rabbit sera. The efficacy of the antibodies was
compared with control IgG purified from rabbits immunized with
an unrelated peptide formulated with the same Freund’s adjuvant.
Rabbit IgG was purified on protein G sepharose (GE Healthcare,
Uppsala, Sweden) and dialyzed against RPMI. Parasitemia in
cultures was estimated after an incubation of 40 hours (one cycle
of invasion in target erythrocytes) by flow cytometry as described
earlier [23,24]. Parasitemia observed in presence of anti-rPfRH240
IgG and control IgGs (5 mg/ml) were used to determine invasion
inhibition rates as described previously [23,24].
Results
Expression and refolding of a recombinant 40 kDa
protein fragment derived from PfRH2a/b (rPfRH240) and
generation of specific PfRH2a/b antibodies
A 366 amino acid sequence (Ser 495 to Ile 860) of PfRH2a/b
(,40 kDa) was chosen for expression on the basis of separate pair
wise clustal alignments of PfRH2b (Genbank AAN39447) with
PfRH1 (Genbank AAQ10315) (Figure S1) and PfRH4 (Genbank
AAM47174) (Figure S2). The pair wise alignments showed regions
of homology in PfRH2a/2b with the erythrocyte binding domains
of PfRH1 and PfRH4 (Figures S1 and S2). The homologous
region is common to both PfRH2a and PfRH2b and lies within
the 2700 amino acid region of their ectodomains that is identical
(PfRH2a/b). The recombinant 40 kDa fragment of PfRH2a/b
(rPfRH240) was expressed with a C-terminal 6-His tag in E. coli in
inclusion bodies, refolded after purification under denaturing
conditions by metal affinity chromatography and further purified
to homogeneity using ion-exchange chromatography (Figure 1A).
Recombinant rPfRH240 was identified in immunoblots using an
anti-His-tag specific antibody (Figure 1B) confirming expression of
the full length 366 amino acid recombinant rPfRH240 protein.
Mice and rabbits were immunized with the recombinant
rPfRH240 protein to produce PfRH2a/b-specific antibodies. High
titer antibodies against the recombinant rPfRH240 protein were
detected in both mice and rabbits with end points observed at
dilutions of 1:320,000 and 1:640,000, respectively (Figure S3). In
addition, we also raised PfRH2a/b mice antibodies against other
regions of the protein, rRH2-Pro1 (amino acids 76–494) and
rRH2-Pro4 (amino acids 1599–2059) (Figures 2A and S4). As the
protein sequence of rPfRH240, rRH2-Pro1 and rRH2-Pro4 is
completely identical between the two PfRH2 homologues, our
antibodies cannot distinguish between PfRH2a and PfRH2b.
Thus, we have termed the parasite protein detected by these
antibodies as PfRH2a/b as they detect the common region from
both proteins, although PfRH2b has been demonstrated to play a
more dominant role in invasion than PfRH2a [16,25].
The specificity of the anti-rPfRH240 antibodies was checked by
localization studies of the PfRH2a/b native protein in merozoites
by immunofluorescence confocal microscopy (details are given in
Materials and Methods S1) using the anti-rPfRH240 polyclonal
mouse sera (Figure S5). The native PfRH2a/b was found to be
localized at the apical pole of the merozoite (Figure S5). PfRH2a/
b co-localizes with the known rhoptry bulb marker protein, clag3.1
demonstrating that it is localized in the rhoptries (Figure S5A). On
the other hand there was no co-localization with the micronemal
marker EBA-175 (Figure S5B). Our data is consistent with
previous reports that have localized PfRH2a/2b in the rhoptries
by immunoelectron microscopy [16] and confirms the specificity
of our PfRH2a/b antibodies.
Detection of processed forms of native PfRH2a/b
To further confirm the specificity of our anti-PfRH2a/b
antibodies, we performed immunoblots using detergent extracts
made from late stage schizonts of P. falciparum lines, 3D7 and
MCamp (Figure 2B). The anti-rPfRH240 antibodies detected three
native proteins by immunoblotting in the range of 220 kDa,
140 kDa and 80 kDa. These proteins were detected only in the
3D7 parasite clone but not in MCamp (Figure 2B). Detection of a
PfRH2a/b protein fragment of around 220 kDa is consistent with
previous reports [10,16,25]. Full length native PfRH2a/b is a
350 kDa protein [9,10]. Presumably the smaller size reflects
proteolytic cleavage of PfRH2a/b produced during schizont
maturation and merozoite formation. To confirm the specificity
of the three protein fragments, we performed immunoblotting with
the anti-PfRH2a/b polyclonal antibodies raised against different
regions of PfRH2a/b, termed as rRH2-Pro1 and rRH2-Pro4
(Figure 2A). rPfRH240 antibodies were raised against amino acids
495 to 860; rRH2-Pro1 antibodies were raised against the region
upstream of rPfRH240 comprising of amino acids 76 to 494;
rRH2-Pro4 antibodies were raised against a region downstream of
rPfRH240 comprising of amino acids 1599 to 2059 (Figure 2A).
We observed that anti-rRH2Pro1 antibodies detected two protein
fragments of 220 kDa and 80 kDa out of the three detected by the
anti-rPfRH240 antibodies (Figure 2B). On the other hand,
antibodies raised against rRH2-Pro4 detected the 220 kDa and
140 kDa proteins only (Figure 2B). The 220 kDa fragment was
detected by all three antibodies confirming its specificity. Apart
from the rPfRH240 antibodies, the lower fragments of 80 kDa and
140 kDa were detected only by the anti-rRH2Pro1 and anti-
rRH2Pro4 antibodies, respectively (Figure 2B). The fact that the
anti-rPfRH240 antibodies detected all three fragments suggested
that all three protein fragments share epitopes recognized by the
polyclonal antibodies. These results implied that the 220 kDa
native PfRH2a/b processed protein was being further processed in
to the 80 kDa and 140 kDa fragments and that the processing was
occurring in between the rPfRH240 region (Figures 2A and B).
Proteolytic processing has been reported for a number of
invasion related parasite proteins [11,13,22–24,27–29]. We have
now demonstrated that like its other PfRH homologues, the
350 kDa native PfRH2 also undergoes processing. Using a higher
concentration of anti-rPfRH240 mouse sera as well as higher
amount of parasite extract from 3D7, we were able to detect bands
in the range of 350 kDa which appear to represent the
PfRH2 Merozoite Protein Binds Human Erythrocytes
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fragments of native PfRH2a/b in line with previous studies
[10,16,25] further confirms the precise specificity of our anti-
PfRH2a/b antibodies.
Further our data is consistent with previous studies that have
shown higher expression of PfRH2a/2b in strains like 3D7 that
use sialic acid independent invasion pathways compared to strains
like MCamp that invade by sialic acid dependent pathways
[16,18,21]. All the three PfRH2a/b antibodies detected native
protein only in 3D7 and not in MCamp. As a control to confirm
that equal amounts of parasite extracts were used in the
immunoblots, we assayed the presence of a nucleosome assembly
protein (NapL), which has a house keeping function and is
expressed equally among different P. falciparum lines [30]. NapL
was found to be present at similar levels in 3D7 and MCamp
(Figure 2B), confirming that equal amounts of 3D7 and MCamp
parasite extract were used. Thus, our results are in agreement with
previous reports on the expression of PfRH2a/2b and confirm the
specificity of our anti-PfRH2a/b sera.
Native PfRH2a/b and recombinant rPfRH240 exhibit
erythrocyte binding activity
The erythrocyte binding characteristics of native PfRH2a/b was
studied in standard erythrocyte binding assays using different
enzyme treated erythrocytes and culture supernatants of purified
P. falciparum schizonts [31,32]. The processed fragments of
PfRH2a/b observed in the parasite detergent based extract were
also found in the culture supernatants. The presence of native
PfRH2a/b among the proteins eluted from the human erythro-
cytes incubated with parasite culture supernatants was detected by
immunoblotting using anti-PfRH2a/b antibodies (Figures 3A and
S6B) and interestingly exhibited differential erythrocyte binding
activity.
The native 220 kDa and 80 kDa processed fragments of
PfRH2a/b were observed to exhibit differential erythrocyte
binding activity. The native 220kDa PfRH2a/b fragment from
culture supernatants bound normal human erythrocytes as well as
neuraminidase-treated erythrocytes and trypsin treated erythro-
cytes (Figures 3A and S6B). The binding of the 220 kDa PfRH2a/
b fragment to erythrocytes was abolished by chymotrypsin
treatment implying that its erythrocyte receptor was chymotrypsin
sensitive (Figures 3A and S6B). Thus, the erythrocyte binding
specificity of the 220 kDa larger fragment of PfRH2a/b was sialic
acid independent, trypsin resistant and chymotrypsin sensitive. On
the other hand, in the same binding experiment, we observed that
the smaller 80 kDa PfRH2a/b fragment exhibited a different
erythrocyte binding phenotype (Figures 3A and S6B). The 80 kDa
fragment bound only with untreated erythrocytes and trypsin
treated erythrocytes but failed to bind with neuraminidase treated
and chymotrypsin treated erythrocytes (Figures 3A and S6B). Thus
the binding phenotype of the 80 kDa smaller processed fragment
of PfRH2a/b was sialic acid dependent, trypsin resistant and
chymotrypsin sensitive.
In parallel control experiments with the same eluate samples,
native EBA-175 bound untreated erythrocytes and chymotrypsin
treated erythrocytes, but not neuraminidase treated erythrocytes
and trypsin treated erythrocytes (Figure 3C). The EBA-175
parasite protein is known not to bind neuraminidase treated
erythrocytes or trypsin treated erythrocytes as its receptor,
glycophorin A, is cleaved after these enzymatic treatments [8].
This result confirms that non-specific binding of parasite culture
supernatant with the erythrocytes was not observed in our assay.
Thus, native PfRH2a/b appears to bind human erythrocytes with
a differential specificity with the different processed fragments of
PfRH2a/b exhibiting a difference in their dependence on sialic
acids to bind human erythrocytes. A number of previous reports
have demonstrated PfRH2 to be involved in sialic acid
independent invasion [16,17,25] and to be highly expressed in
sialic acid independent clones compared to sialic acid dependent
clones [16,18,21]. The erythrocyte binding phenotype of the
220 kDa processed fragment is consistent with these former
reports. While in this context, the physiological significance of the
erythrocyte binding profile of the 80 kDa fragment is yet not clear,
it may be possible that the same protein after processing may be
interacting with different erythrocyte receptors.
The erythrocyte binding activity of rPfRH240 was also studied in
similar erythrocyte binding assays. The rPfRH240 recombinant
protein also bound erythrocytes with the same specificity as the
Figure 1. Expression and purification of the recombinant rPfRH240 protein. The 366 amino acid region (Ser495 to Ile860) common to both
PfRH2a and PfRH2b was expressed and purified to homogeneity. (A) The purified protein was analyzed on an SDS-PAGE under reducing (R) and non-
reducing (NR) conditions. (B) The purified recombinant protein was detected in immunoblots under reducing and non-reducing conditions by using
an anti-His tag antibody.
doi:10.1371/journal.pone.0017102.g001
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neuraminidase treated and trypsin treated erythrocytes but not
chymotrypsin treated erythrocytes. Along with rPfRH240, we also
examined the erythrocyte binding of two recombinant proteins –
EBA-175 Region II (rEBA-175RII) and PfRH4 (rPfRH430)a s
controls in the same assay [23,33]. EBA175 RII is the erythrocyte
binding domain of the native EBA-175 protein [8]. Thus, similar to
the native protein, rEBA175RII was observed to bind untreated
erythrocytes and chymotrypsin treated erythrocytes, but not to
neuraminidase treated erythrocytes and trypsin treated erythrocytes
(Figure 3D). The PfRH4 recombinant protein, rPfRH430, has been
reported earlier to bind erythrocytes in sialic acid independent
(neuraminidase resistant), trypsin and chymotrypsin sensitive
manner [23,24]. Consistent with previous reports, we found that
the recombinant rPfRH430 protein bound neuraminidase treated
erythrocytes but failed to bind with trypsin or chymotrypsin treated
erythrocytes (Figure 3E). These control binding assays demonstrat-
ed the erythrocyte binding characteristics of known invasion
proteins consistent with their previously reported phenotypes
confirming the specificity of our erythrocyte binding assay and
ensuring the optimal enzymatic treatment of the erythrocytes.
Antibodies to rPfRH240 blocked erythrocyte invasion
Since PfRH2a/b is involved in erythrocyte invasion with an
erythrocyte binding role and the rPfRH240 region binds with the
same specificity as the native protein, we tested if antibodies
against rPfRH240 could block erythrocyte invasion. We measured
the invasion inhibitory activity of purified rabbit IgG raised against
rPfRH240 in standard GIA (growth inhibition assays) as described
earlier [23,24]. Anti-rPfRH240 rabbit IgG blocked invasion of
normal untreated erythrocytes by the 3D7 parasite line by 25%
(Figure 4). Since, PfRH2a/b mediates invasion through the sialic
acid independent, trypsin resistant pathway, we tested the GIA
activity of the PfRH2a/b antibodies for invasion into neuramin-
idase and trypsin treated erythrocytes. The 3D7 parasite line has a
sialic acid independent, trypsin resistant invasion phenotype. With
neuraminidase treated erythrocytes and trypsin treated erythro-
cytes, the percent inhibition (Figure 4) was higher (50–53%) than
that observed for invasion into normal erythrocytes indicating that
under conditions where the 3D7 parasite is restricted to invade
through only sialic acid independent or trypsin resistant pathways,
the invasion inhibition was more efficient. Further, the invasion
inhibition of the purified IgG could be neutralized by the addition
of recombinant rPfRH240 protein (30 mg/ml), which clearly
demonstrated that the invasion inhibition was specifically due to
the anti- rPfRH240 antibodies. To further confirm the GIA
specificity of our antibodies, we tested the GIA activity of the anti-
PfRH240 antibodies with the P. falciparum clone Dd2 that invades
only through sialic acid dependent pathways (Figure 4). The anti-
rPfRH240 antibodies did not exhibit any invasion inhibition effect
Figure 2. The native PfRH2a/b protein is processed and its expression varies between different parasite lines. (A) A schematic
representation of the protein structure of PfRH2a/2b and the different regions against which specific PfRH2a/b antibodies have been raised are
shown. In line with the immunoblot results, the steps of processing and the resulting PfRH2a/b fragments are depicted. Native full length PfRH2a/b
undergoes processing to produce a 220 kDa fragment, which is further processed between the amino acids 495–860 to produce two fragments of
80 kDa and 140 kDa. (B) Immunoblots of parasite extracts from the 3D7 and MCamp clones detected by the three PfRH2a/b antibodies. The three
antibodies detected PfRH2a/b processed fragments (marked by arrows) only in 3D7, a sialic acid independent clone, and not in MCamp, a sialic acid
dependent clone. Antiserum against NapL, a nuclear accessory protein, was used to confirm that an equal amount of parasite extract was used in the
immunoblots.
doi:10.1371/journal.pone.0017102.g002
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not involved in sialic acid dependent invasion pathways and
further confirms the specific invasion inhibitory effect of anti-
PfRH2a/b antibodies.
Discussion
P. falciparum exhibits a redundancy in its repertoire of invasion
molecules that enables it to invade human erythrocytes through
multiple pathways [5–7]. One family of parasite molecules that
mediates P. falciparum erythrocyte invasion is the P. falciparum
reticulocyte homology (PfRH) proteins [5–7]. These proteins are
homologous to the P. vivax reticulocyte binding proteins (PvRBP-
1/2) which mediate specific invasion of reticulocytes by P. vivax
[34]. P. falciparum does not exhibit any preference for reticulocyte
invasion and the PfRH homologues bind mature human
erythrocytes during invasion [5–7].
PfRH1 has been shown to bind erythrocytes in a sialic acid
dependent, trypsin resistant, chymotrypsin resistant manner
[11,21,22]. Like EBA-175, PfRH1 has been shown to be a major
ligand for sialic acid dependent invasion as all sialic acid
dependent clones express high levels of PfRH1 [21]. PfRH4 is
another PfRH protein which has clearly been shown to bind
erythrocytes [23,24]. The importance of PfRH4 was realized by its
upregulation in experiments that mediated an invasion switch in
the Dd2 (W2mef) clone from sialic acid dependent to sialic acid
independent pathways [19,20]. PfRH4 has been shown to bind in
a sialic acid independent, trypsin sensitive and chymotrypsin
sensitive manner [23,24]. PfRH5 is the third protein of the family
that has been shown to bind human erythrocytes [13,30]. PfRH5
has also been proven to mediate invasion of Aotus erythrocytes by
Figure 3. Erythrocyte binding activity of native PfRH2a/b and recombinant rPfRH240 proteins. (A) Binding of the native PfRH2a/b protein
in 3D7 culture supernatants incubated with untreated (U) erythrocytes, different enzyme-treated erythrocytes (Nm: neuraminidase-treated; T: trypsin-
treated; C: chymotrypsin-treated). The processed PfRH2a/b parasite protein fragments (220 kDa and 80 kDa) were detected in the eluate fractions by
immunoblotting using the anti-rPfRH240 antibodies. (B) Binding of the recombinant rPfRH240 protein with a similar set of erythrocytes. (C) Binding of
native EBA-175 from 3D7 parasite culture supernatant with different enzyme treated erythrocytes. (D) Binding of recombinant EBA-175 region II
(rEBA-175 RII) with enzyme treated erythrocytes. (E) Binding of recombinant PfRH4 (rRH430) region (amino acids 328–588) with enzyme treated
erythrocytes.
doi:10.1371/journal.pone.0017102.g003
Figure 4. Invasion inhibitory activity ofanti-rPfRH240 antibodies.
Rabbit purified IgG against rPfRH240 was tested for its invasion
inhibitory activity against the 3D7 and Dd2 parasite clones. Rabbit
anti-PfRH240 IgG blocked invasion of normal untreated erythrocytes by
the 3D7 parasite line by 25% and with neuraminidase treated
erythrocytes and trypsin treated erythrocytes, the percent inhibition
was 50–53%. The anti-rPfRH240 antibodies did not exhibit any invasion
inhibition effect on Dd2 with untreated erythrocytes. The invasion
inhibitory activity with neuraminidase treated erythrocytes was not
tested for Dd2 as the Dd2 parasite clone is sialic acid dependent and
fails to invade neuraminidase treated erythrocytes. For studying
the reversal of antibody inhibition, rPfRH240, was added at a final
concentration of 30 mg/ml.
doi:10.1371/journal.pone.0017102.g004
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polymorphisms in PfRH5 have been shown to determine receptor
binding specificity [13]. PfRH3 is a pseudogene that is transcribed
but not translated [15].
Recently a number of reports have elucidated the erythrocyte
binding region of PfRH proteins. The first receptor binding region
of PfRH proteins was identified for PfRH4 [23]. This was followed
by further studies on PfRH1 [22] and PfRH4 [24], which mapped
the receptor binding region by analyzing the binding activity of
several overlapping fragments of the PfRH proteins. PfRH1 and
PfRH4 are homologous in their N-terminal regions, which have
been shown to mediate erythrocyte binding [22–24].
Despite being a member of a family of erythrocyte binding
proteins, PfRH2a/2b had not been shown to bind erythrocytes.
While it was clear from previous reports that PfRH2a/2b has a
role in invasion [16], this is the first report to demonstrate that
PfRH2a/2b exhibits erythrocyte binding activity. We expressed
and purified a 366 amino acid region near the N-terminal of the
PfRH2a/b ectodomain (rPfRH240). This region was chosen on the
basis of its homology in pair wise clustal alignments with the
erythrocyte binding regions of PfRH1 and PfRH4. Like the
cysteine rich regions of the DBLs, PfRH proteins lack any highly
conserved regions that would obviously appear to constitute a
globular functional domain. The rPfRH240 region contains one
cysteine. The rPfRH240 sequence of interest was codon optimized
to obtain maximum expression in E. coli. The recombinant protein
was expressed in an insoluble form as inclusion bodies and was
refolded. The refolded and purified protein was used to immunize
mice and rabbits to generate specific antibodies against PfRH2a/
b. The recombinant protein was found to be highly immunogenic
in both mice and rabbits.
Antibodies raised against rPfRH240 localized the native proteins
in the rhoptries. This is consistent with previous immune electron
microscopy studies that demonstrated localization of PfRH2a/b in
the rhoptries [16]. Further, in line with previous studies, we
observed higher levels of expression of PfRH2a/b in a sialic acid
independent clone 3D7 compared to a sialic acid dependent clone,
MCamp. These results confirmed the specificity of our PfRH2a/b
antibodies.
The anti-rPfRH240 antibodies detected processed fragments of
native PfRH2a/b protein in parasite extracts and culture
supernatants by immunoblotting consistent with previous studies
[10,16,25]. Proteolytic processing is a phenomenon that has been
studied and well established for a number of parasite proteins
involved in erythrocyte invasion such as MSP-1, AMA-1, PfRH1,
PfRH4 and PfRH5 [11,13,21–24,27–29,37,38]. Proteolytic pro-
cessing of invasion ligands is mediated by a vast repertoire of
parasite proteases such as rhomboids and subtilisins during
invasion [37].
Polyclonal antibodies raised against rPfRH240 (Ser 495 to Ile
860) detected protein fragments of around 220 kDa, 140 kDa and
80 kDa. The fact that anti-rPfRH240 polyclonal antibodies
specifically detected several fragments implied that all the three
fragments contain epitopes that could be recognized by the
antibodies. It thus appeared that the 220 kDa processed fragment
of PfRH2a/b protein was being further processed into smaller
fragments. This was confirmed by immunoblotting experiments
using antibodies raised against different regions of PfRH2a/b. We
raised polyclonal antibodies against two different regions of
PfRH2, anti-rRH2Pro1 raised against amino acids 76–494 and
anti-rRH2Pro4 raised against amino acids 1599–2059. The
immunoblots of parasite extracts with these two antibodies
confirmed our model of PfRH2 processing as shown in
Figure 2A. All the three antibodies detected the 220 kDa
processed fragment of native PfRH2. Further, antibodies only
against rRH2-Pro1 (76–494) and rPfRH240 (495–860) detected the
80 kDa fragment while the antibodies only against rPfRH240
(495–860) and rRH2-Pro4 (1599–2059) detected the 140 kDa
fragment. This clearly demonstrated that the 220 kDa native
PfRH2a/b protein was being further processed between the amino
acids 495–860 yielding the 80 kDa fragment towards the N-
terminus and the 140 kDa fragment towards the C-terminus as
shown in Figure 2A. While, we do not yet know the precise sites of
processing of PfRH2a/b, we speculate that full length native
PfRH2a/b might be processed between the amino acids 30–123 at
the N-terminus and 2030–2123 towards the C-terminus to yield
the 220 kDa fragment, which is further processed approximately
between the amino acids 760–850 to yield the 80 kDa and
140 kDa fragments. The sequential processing observed for
PfRH2 has been previously well reported for MSP-1 [27] and
PfRH1 [38]. While our report is the first to demonstrate
processing of PfRH2, more work will be required to understand
the precise mechanism of PfRH2 processing and its physiological
significance for the parasite.
While PfRH2 was observed to be processed, it was clear that
only the 220 kDa and 80 kDa fragments exhibited erythrocyte
binding activity. However the specificity of the binding was
observed to be different with respect to their use of sialic acids as a
component of their erythrocyte receptors. The erythrocyte binding
specificity of the native 220 kDa PfRH2a/b fragment was sialic
acid independent, trypsin resistant and chymotrypsin sensitive.
This binding phenotype suggests that the erythrocyte receptor to
which the 220 kDa PfRH2a/b protein binds does not comprise of
sialic acid moieties as neuraminidase treatment had no effect on its
erythrocyte binding. Similarly the receptor is trypsin resistant as
the 220 kDa PfRH2a/b protein bound trypsin treated erythro-
cytes. However, since the binding of the 220 kDa PfRH2a/b
protein was abolished with chymotrypsin treatment, its erythrocyte
receptor is chymotrypsin sensitive. On the other hand, the smaller
80 kDa processed fragment of PfRH2a/b was observed to bind
erythrocytes in a sialic acid dependent, trypsin resistant,
chymotrypsin sensitive manner. The erythrocyte binding activity
of both 220 kDa and the 80 kDa fragments was confirmed by
PfRH2a/b antibodies raised against rPfRH240 and rRH2-Pro1.
Thus, while the differential erythrocyte binding activity of the two
processed fragments of PfRH2 is a consistent observation, the
physiological significance of this differential erythrocyte binding
activity of the lower 80 kDa fragment is not clear. Our
observations are similar to the case of erythrocyte binding of
EBA-175 which has been shown to bind Glycophorin A in a sialic
acid dependent manner [8,31]. The full length protein was shown
to bind erythrocytes in a culture supernatant based erythrocyte
binding assay [31] and the domain (region II) responsible for
mediating the binding has been identified and characterized [8].
However, in addition a 65 kDa processed fragment of EBA-175
has also been reported to bind erythrocytes in a sialic acid
independent manner [39]. Thus while EBA-175 has been
conclusively proven to bind glycophorin A and mediate invasion
through the sialic acid dependent pathway, the physiological
significance of the binding of the 65 kDa fragment remains
unclear.
This specificity of erythrocyte binding of the native PfRH2a/b is
consistent with a previous knockout study, which on the basis of
differences in the invasion phenotypes between the PfRH2b knock
out and wild type parasite lines, had demonstrated PfRH2b to play
a role in a sialic acid independent, trypsin resistant, chymotrypsin
sensitive invasion pathway [16]. Both PfRH2a and PfRH2b were
knocked out individually in the 3D7 parasite clone and the
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PfRH2b knock out line was observed to invade neuraminidase
treated and trypsin treated erythrocytes at a lower efficiency
suggesting that the loss of the gene had compromised the parasite’s
invasion efficiency to invade through the neuraminidase resistant
(sialic acid independent) and trypsin resistant pathway [16]. On
the other hand, the PfRH2b knock out displayed a higher rate of
invasion with chymotrypsin treated erythrocytes inferring that the
loss of the gene was allowing the parasite to invade better through
the chymotrypsin resistant pathway and further implying PfRH2b
to be involved in a chymotrypsin sensitive pathway [16]. Thus,
while no direct evidence for erythrocyte binding of PfRH2b was
reported, the knock out study showed that PfRH2b is involved in
erythrocyte invasion and interacts with a sialic acid independent,
trypsin resistant and chymotrypsin sensitive Receptor Z [16].
The PfRH2a knock out parasite line did not display any
difference in invasion compared to the wild type 3D7 clone, which
clearly suggested that PfRH2b had a more dominant role in
erythrocyte invasion than PfRH2a in 3D7. This was further
confirmed in another knock out study that found a stronger
selection pressure for the reconstitution of PfRH2b expression at
the expense of PfRH2a [25]. Further, genetic insertion of the
PfRH2b gene in the D10 clone that endogenously lacks the
PfRH2b gene but expresses PfRH2a significantly increased the
efficiency of the transfected parasite line to invade neuraminidase
and trypsin treated erythrocytes and simultaneously reduced its
efficiency to invade chymotrypsin treated erythrocytes [17]. These
results further substantiated the dominant role of PfRH2b over
PfRH2a and confirmed its role in a sialic acid independent, trypsin
resistant, chymotrypsin sensitive invasion pathway. However, a
role of PfRH2a was demonstrated in the sialic acid independent
pathway as knockouts of PfRH2a in the W2mef/Nm switched
parasites reduced their efficiency to invade through the sialic acid
independent pathway [16]. Thus, inspite of the high identity
between PfRH2a and PfRH2b and the fact that our antibodies
raised against a common region cannot differentiate between the
two homologues, it is highly probable that our results reflect the
functional activity of the dominant PfRH2b homologue as
PfRH2b has a more dominant role in erythrocyte invasion than
PfRH2a. Most importantly, we have demonstrated for the first
time that the processed form of PfRH2a/b possesses erythrocyte
binding activity and is involved in sialic acid independent invasion.
Previously published PfRH2 antibodies were raised against regions
near the C-terminal and not against the N-terminal region that
exhibits erythrocyte binding activity [10,16]. This is probably a
major reason as to why previous studies have failed to detect
erythrocyte binding of PfRH2 as the appropriate antibodies that
could detect the processed N-terminal PfRH2 fragments were not
used for erythrocyte binding assays.
Another significant finding of our work is the elucidation of the
erythrocyte binding domain of PfRH2a/b. We have mapped the
domain to a 40 kDa region (rPfRH240, amino acids 495–860) that
binds erythrocytes with the same specificity as that of the native
220 kDa PfRH2a/b protein and is consistent with the role of
PfRH2a/b in the sialic acid independent, trypsin resistant and
chymotrypsin sensitive pathway. We also found that antibodies
against PfRH2a/b blocked erythrocyte invasion. Since, PfRH2b is
a major parasite ligand mediating sialic acid independent invasion,
we tested the ability of PfRH2a/b antibodies to block invasion of
neuraminidase treated erythrocytes and observed that invasion
blocking with neuraminidase treated erythrocytes is higher than
with untreated normal erythrocytes. The reason for this higher
invasion blocking efficiency is that with normal untreated
erythrocytes, the parasites have a number of ligand-receptor
interactions at its disposal to mediate successful invasion. These
include both sialic acid dependent and independent parasite
molecules. With neuraminidase treatment, the parasite is restricted
to use only sialic acid independent pathways while other sialic acid
dependent pathways are unavailable due to the removal of sialic
acid moieties on the erythrocyte surface. Therefore, the PfRH2a/
b antibodies blocked invasion of neuraminidase treated erythro-
cytes more efficiently than that of normal untreated erythrocytes.
To prove that this inhibition was primarily due to antibodies
against PfRH2, we were able to demonstrate that antibody
inhibition could be neutralized by adding recombinant protein in
the invasion assay well. This was further confirmed in invasion
assays with the Dd2 parasite clone that invades erythrocytes only
through sialic acid dependent pathways. Since PfRH2 is involved
in sialic acid independent invasion, it would not be expected to
block invasion by Dd2 parasites which do not use sialic acid
independent pathways. Our invasion assay results were consistent
with this prediction as anti-rPfRH240 antibodies did not block
erythrocyte invasion by the Dd2 clone.
Recently published data has shown that the N-terminal region
of PfRH2 is more polymorphic than the rest of the protein and is a
target of protective immunity against P. falciparum malaria [40]. An
analysis of PfRH2 sequences among 33 parasite lines showed that
the region (amino acids 212–745) was most polymorphic and
suggested that it was under diversifying selection due to immune
pressure [40]. The study found human antibodies against this N-
terminal region showed the strongest association with protection
from high density parasitemia. The polymorphic N-terminal
region of PfRH2 has a substantial overlap with the rPfRH240
region (amino acids 495–860) that we have demonstrated to be the
erythrocyte binding domain of PfRH2a/b. It is evident that
protein domains that bind with the host erythrocyte would be
exposed to the immune system and thus be under immune
pressure. Thus, this recent data further substantiates our finding of
the erythrocyte binding domain of PfRH2.
The identification of the erythrocyte binding regions of invasion
proteins is important as it helps in demarcating the critical
functional domains of such large molecular weight proteins that
could be further developed as sub-unit vaccines. We have not only
demonstrated for the first time that PfRH2a/b like its other
paralogues of the PfRH family is an erythrocyte binding protein,
our report has also identified the functional domain of the PfRH2
protein that is responsible for mediating erythrocyte binding. We
have expressed a region of PfRH2a/b that was homologous to the
erythrocyte binding regions of PfRH1 and PfRH4. However, the
exact boundaries of the receptor binding domain of PfRH2a/b
remains to be further mapped. It is still possible that other regions
of PfRH2a/b are also involved in erythrocyte binding and may
come together in the three-dimensional structure to fully constitute
the erythrocyte binding domain. The three dimensional structure
of PfRH proteins has yet not been reported. As our understanding
of the functional domains of the PfRH proteins has improved, the
next challenge is the complete elucidation of the structure of the
PfRH proteins. Thus, further research would be needed to
completely dissect the structural and functional role of the PfRH
proteins in merozoite invasion.
Supporting Information
Materials and Methods S1 The Methodology used to study
the localization of PfRH2a/b by immunofluorescence confocal
microscopy is described.
(DOC)
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with the amino acid sequence of PfRH1. Pairwise clustal
alignment of the PfRH2b (Genbank number AAN39447) protein
sequence with PfRH1 (Genbank number AAQ10315). The 366
amino acid sequence of PfRH2a/b selected for recombinant
expression (Ser 495 to Ile 860) is highlighted in the boxes. ‘‘*’’
identical residues; ‘‘:’’ conserved substitutions; ‘‘.’’ semi-conserved
substitutions.
(TIF)
Figure S2 Alignment of the PfRH2b protein sequence
with the amino acid sequence of PfRH4. Pairwise clustal
alignment of the PfRH2b (Genbank number AAN39447) protein
sequence with PfRH4 (Genbank number AAM47174). The 366
amino acid sequence of PfRH2a/b selected for recombinant
expression (Ser 495 to Ile 860) is highlighted in the boxes. ‘‘*’’
identical residues; ‘‘:’’ conserved substitutions; ‘‘.’’ semi-conserved
substitutions.
(TIF)
Figure S3 Immunogenicity of the recombinant
rPfRH240 protein. (A) The titers of antibodies raised against
rPfRH240 in five mice were measured in standardized ELISA.
Three control mice immunized with adjuvant alone were also
analyzed. Titers in the three control mice at a dilution of 1:1000
were extremely low and similar to the titers of the pre-immune
sera from the five immunized mice. (B) Titers of anti-PfRH240
antibodies were measured in rabbit sera. High titer antibodies (end
point observed at dilution of 1:320,000 in mice and 1:640,000 in
rabbits) against the recombinant rPfRH240 protein were detected.
(TIF)
Figure S4 SDS-PAGE of metal affinity chromatography
purified proteins raised against different regions in the
ectodomain of PfRH2a/b. (A) rRH2-Pro1 (amino acids 76-
494) and (B) rRH2-Pro4 (amino acids 1599-2059). The partially
purified proteins were eluted from acrylamide and immunized in
mice.
(TIF)
Figure S5 Localization of PfRH2a/b by immunofluo-
rescence confocal microscopy. (A) 3D7 schizonts were dual
labeled with anti-rPfRH240 mice sera and anti-clag3.1 rabbit sera.
Mature schizonts immunolabeled with anti-rPfRH240 were stained
with Alexa 488 linked anti-mouse IgG secondary antibody (green).
Schizonts labeled with anti-clag3.1 rabbit sera were stained with
Alexa 594 linked anti-rabbit IgG secondary antibody (red). (B)
3D7 mature schizonts were dual labeled with anti-rPfRH240
mouse sera and anti-EBA175 rabbit sera. Schizonts labeled with
anti-EBA-175 antibodies were stained with Alexa 594 linked anti-
rabbit IgG secondary antibody (red). PfRH2a/b co-localizes with
the known rhoptry marker protein, clag3.1 and not with the
microneme marker protein, EBA-175.
(TIF)
Figure S6 (A) Full length native PfRH2a/b and its processed
forms were detected in 3D7 parasite extracts by using a higher
concentration of anti-rPfRH240 sera. (B) Binding of the native
PfRH2a/b protein in 3D7 culture supernatants incubated with
untreated (U) erythrocytes, different enzyme-treated erythrocytes
(Nm: neuraminidase-treated; T: trypsin-treated; C: chymotrypsin-
treated). The processed 220 kDa and 80 kDa PfRH2a/b parasite
proteins were detected in the eluate fractions by immunoblotting
using antibodies against the rRH2-Pro1 region.
(TIF)
Acknowledgments
We wish to thank Dr Louis H. Miller for providing reagents for the study.
The authors are grateful to Professor Virander S. Chauhan, Director
(ICGEB) for providing all the necessary facilities for conducting the
experiments and critically reviewing the manuscript. The technical
assistance of Dr D. B. Chandramouli, Rakesh Kumar Singh and Ashok
Das from the ICGEB animal facility in performing the animal experiments
is deeply appreciated.
Author Contributions
Conceived and designed the experiments: DG. Performed the experiments:
TS KSR MB AKP SS. Analyzed the data: CEC DG. Contributed
reagents/materials/analysis tools: CEC DG. Wrote the manuscript: CEC
DG.
References
1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global
distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:
214–217.
2. Miller LH, Mason SJ, Clyde DF, McGinniss MH (1976) The resistance factor to
Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med
295: 302–304.
3. Adams JH, Hudson DE, Torii M, Ward GE, Wellems TE, et al. (1990) The
Duffy receptor family of Plasmodium knowlesi is located within the micronemes of
invasive malaria merozoites. Cell 63: 141–153.
4. Chitnis CE, Miller LH (1994) Identification of the erythrocyte binding domains
of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte
invasion. J Exp Med 180: 497–506.
5. Gaur D, Mayer DC, Miller LH (2004) Parasite ligand-host receptor interactions
during invasion of erythrocytes by Plasmodium merozoites. Int J Parasitol 34:
1413–29.
6. Cowman AF, Crabb BS (2006) Invasion of red blood cells by malaria parasites.
Cell 124: 755–66.
7. Iyer J, Gruner AC, Renia L, Snounou G, Preiser PR (2007) Invasion of host cells
by malaria parasites: a tale of two protein families. Mol Microbiol 65: 231–49.
8. Sim BK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH (1994) Receptor
and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science
264: 1941–1944.
9. Rayner JC, Galinski MR, Ingravallo P, Barnwell JW (2000) Two Plasmodium
falciparum genes express merozoite proteins that are related to Plasmodium vivax
and Plasmodium yoelii adhesive proteins involved in host cell selection and
invasion. Proc Natl Acad Sci U S A 97: 9648–9653.
10. Triglia T, Thompson J, Caruana SR, Delorenzi M, Speed T, et al. (2001)
Identification of proteins from Plasmodium falciparum that are homologous to
reticulocyte binding proteins in Plasmodium vivax. Infect Immun 69(2): 1084–92.
11. Rayner JC, Vargas-Serrato E, Huber CS, Galinski MR, Barnwell JW (2001) A
Plasmodium falciparum homologue of Plasmodium vivax reticulocyte binding protein
(PvRBP1) defines a trypsin-resistant erythrocyte invasion pathway. J Exp Med
194: 1571–1581.
12. Kaneko O, Mu J, Tsuboi T, Su X, Torii M (2002) Gene structure and
expression of a Plasmodium falciparum 220-kDa protein homologous to the
Plasmodium vivax reticulocyte binding proteins. Mol Biochem Parasitol 121:
275–278.
13. Hayton K, Gaur D, Liu A, Takahashi J, Henschen B, et al. (2008) Erythrocyte
binding protein PfRH5 polymorphisms determine species-specific pathways of
Plasmodium falciparum invasion. Cell Host Microbe 4(1): 40–51.
14. Triglia T, Thompson JK, Cowman AF (2001) An EBA175 homologue which is
transcribed but not translated in erythrocytic stages of Plasmodium falciparum. Mol
Biochem Parasitol 116: 55–63.
15. Taylor HM, Triglia T, Thompson J, Sajid M, Fowler R, et al. (2001) Plasmodium
falciparum homologue of the genes for Plasmodium vivax and Plasmodium yoelii
adhesive proteins, which is transcribed but not translated. Infect Immun 69:
3635–3645.
16. Duraisingh MT, Triglia T, Ralph SA, Rayner JC, Barnwell JW, et al. (2003)
Phenotypic variation of Plasmodium falciparum merozoite proteins directs receptor
targeting for invasion of human erythrocytes. EMBO J 22: 1047–1057.
17. Dvorin JD, Bei AK, Coleman BI, Duraisingh MT (2010) Functional
diversification between two related Plasmodium falciparum merozoite invasion
PfRH2 Merozoite Protein Binds Human Erythrocytes
PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e17102ligands is determined by changes in the cytoplasmic domain. Mol Microbiol
75(4): 990–1006.
18. Taylor HM, Grainger M, Holder AA (2002) Variation in the expression of a
Plasmodium falciparum protein family implicated in erythrocyte invasion. Infect
Immun Oct;70(10): 5779–89.
19. Stubbs J, Simpson KM, Triglia T, Plouffe D, Tonkin CJ, et al. (2005) Molecular
mechanism for switching of P. falciparum invasion pathways into human
erythrocytes. Science 309: 1384–7.
20. Gaur D, Furuya T, Mu J, Jiang LB, Su X Zetal (2006) Upregulation of
expression of the reticulocyte homology gene 4 in the Plasmodium falciparum clone
Dd2 is associated with a switch in the erythrocyte invasion pathway. Mol
Biochem Parasitol 145: 205–15.
21. Triglia T, Duraisingh MT, Good RT, Cowman AF (2005) Reticulocyte-binding
protein homologue 1 is required for sialic acid-dependent invasion into human
erythrocytes by Plasmodium falciparum. Mol Microbiol 55(1): 162–74.
22. Gao X, Yeo KP, Aw SS, Kuss C, Iyer JK, et al. (2008) Antibodies targeting the
PfRH1 binding domain inhibit invasion of Plasmodium falciparum merozoites.
PLoS Pathog 4(7): e1000104.
23. Gaur D, Singh S, Singh S, Jiang L, Diouf A, et al. (2007) Recombinant
Plasmodium falciparum reticulocyte homology protein 4 binds to erythrocytes and
blocks invasion. Proc Natl Acad Sci U S A 104: 17789–17794.
24. Tham WH, Wilson DW, Reiling L, Chen L, Beeson JG, et al. (2009) Antibodies
to reticulocyte binding protein-like homologue 4 inhibit invasion of Plasmodium
falciparum into human erythrocytes. Infect Immun 77(6): 2427–35.
25. Desimone TM, Jennings CV, Bei AK, Comeaux C, Coleman BI, et al. (2009)
Cooperativity between Plasmodium falciparum adhesive proteins for invasion into
erythrocytes. Mol Microbiol 72(3): 578–89.
26. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, et al. (2005)
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage
vaccine for Plasmodium falciparum malaria. Infect Immun 73: 3677–85.
27. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA (1990) A
single fragment of a malaria merozoite surface protein remains on the parasite
during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp
Med 172(1): 379–82.
28. Howell SA, Withers-Martinez C, Kocken CH, Thomas AW, Blackman MJ
(2001) Proteolytic processing and primary structure of Plasmodium falciparum
apical membrane antigen-1. J Biol Chem 276(33): 31311–20.
29. Baum J, Chen L, Healer J, Lopaticki S, Boyle M, et al. (2009) Reticulocyte-
binding protein homologue 5 - an essential adhesin involved in invasion of
human erythrocytes by Plasmodium falciparum. Int J Parasitol 39(3): 371–80.
30. Chandra BR, Olivieri A, Silvestrini F, Alano P, Sharma A (2005) Biochemical
characterization of the two nucleosome assembly proteins from Plasmodium
falciparum. Mol Biochem Parasitol 142(2): 237–47.
31. Camus D, Hadley TJ (1985) A Plasmodium falciparum antigen that binds to host
erythrocytes and merozoites. Science 230: 553–6.
32. Mayer DC, Kaneko O, Hudson-Taylor D E, Reid ME, Miller LH (2001)
Characterization of a Plasmodium falciparum erythrocyte-binding protein para-
logous to EBA-175. Proc Natl Acad Sci U S A 98: 5222–7.
33. Liang H, Narum DL, Fuhrmann SR, Luu T, Sim BK (2000) A recombinant
baculovirus-expressed Plasmodium falciparum receptor-binding domain of eryth-
rocyte binding protein EBA-175 biologically mimics native protein. Infect
Immun Jun;68(6): 3564–8.
34. Galinski MR, Medina CC, Ingravallo P, Barnwell JW (1992) A reticulocyte-
binding protein complex of Plasmodium vivax merozoites. Cell 69: 1213–1226.
35. Mayer DC, Mu JB, Feng X, Su XZ, Miller LH (2002) Polymorphism in a
Plasmodium falciparum erythrocyte-binding ligand changes its receptor specificity.
J Exp Med 196(11): 1523–8.
36. Mayer DC, Mu J, Kaneko O, Duan J, Su XZ, et al. (2004) Polymorphism in the
Plasmodium falciparum erythrocyte-binding ligand JESEBL/EBA-181 alters its
receptor specificity. Proc Natl Acad Sci U S A 101: 2518–23.
37. Blackman MJ (2004) Proteases in host cell invasion by the malaria parasite. Cell
Microbiol 6(10): 893–903.
38. Triglia T, Tham WH, Hodder A, Cowman AF (2009) Reticulocyte binding
protein homologues are key adhesins during erythrocyte invasion by Plasmo-
dium falciparum. Cell Microbiol Nov;11(11): 1671–87.
39. Kain KC, Orlandi PA, Haynes JD, Sim KL, Lanar DE (1993) Evidence for two-
stage binding by the 175-kD erythrocyte binding antigen of Plasmodium falciparum.
J Exp Med 1993 Nov 1;178(5): 1497–505.
40. Reiling L, Richards JS, Fowkes FJ, Barry AE, Triglia T, et al. (2010) Evidence
that the erythrocyte invasion ligand PfRh2 is a target of protective immunity
against Plasmodium falciparum malaria. J Immunol Nov 15;185(10): 6157–67.
PfRH2 Merozoite Protein Binds Human Erythrocytes
PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e17102